All In Biotech

Free tool

FAERS Monitor: Pemazyre

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213736 or its brand name (Pemazyre, Pemigatinib). Reports on generic versions are filed under their own applications.

Reports

853

Serious

532

62% of reports

Hospitalization

205

Death reported

150

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use155
  • disease progression144
  • death86
  • fatigue82
  • alopecia67
  • cholangiocarcinoma62
  • hyperphosphataemia54
  • drug ineffective48
  • diarrhoea46
  • nausea43
  • constipation40
  • hospitalisation40
  • decreased appetite37
  • dry mouth35
  • stomatitis35

Reports by year received

View as table
YearReports
2020101
202189
202266
2023279
2024123
202595
2026100

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,306 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cholangiocarcinomaSignal621071.6838.562,539
hyperphosphataemiaSignal54635.3489.032,726
disease progressionSignal14430.025.94,032
stomatitisSignal3514.210.3419
dry mouthSignal3510.67.7297
alopeciaSignal678.46.7434
hospitalisationSignal406.44.7179
constipationSignal404.53.3107
off label useSignal1554.43.8416
decreased appetiteSignal373.92.979
fatigueSignal822.62.182
deathSignal862.52.076
diarrhoea461.81.315
nausea431.31.04
drug ineffective480.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.